The trajectory of fatigue-related symptom clusters and influencing factors in patients with lung cancer receiving immunotherapy
10.3781/j.issn.1000-7431.2024.2406-0342
- VernacularTitle:肺癌免疫治疗患者疲乏相关症状群变化轨迹及其影响因素
- Author:
Nana PENG
1
;
Zhenqi LU
;
Jialei WANG
;
Zhihuang HU
;
Fengzhen CHEN
;
Xiaoju ZHANG
Author Information
1. 复旦大学附属肿瘤医院护理部,上海 200032;复旦大学上海医学院肿瘤学系,上海 200032
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Immunotherapy;
Fatigue;
Symptom trajectory;
Growth mixture model
- From:
Tumor
2024;44(7):693-707
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To identify the trajectory of fatigue-related symptom clusters(fatigue-decreased appetite-pain)in patients with lung cancer receiving immunotherapy and their influencing factors.Methods:From March 2022 to March 2023,114 patients with lung cancer receiving immunotherapy for the first time in Fudan University Shanghai Cancer Center were selected as research subjects.A 6-month longitudinal follow-up was performed using the PRO-CTCAE-based subset for lung cancer immunotherapy,and the demographic,disease physiological,psychological,social and healthy lifestyle data of patients were collected before the first dose.Growth mixed model and logistic regression analysis were used to identify the trajectory categories and influencing factors of fatigue-related symptom clusters.Results:Two fatigue trajectories of patients with lung cancer receiving immunotherapy were identified,named"mild to moderate fatigue persistent group"and"mild fatigue production-relief group".Three trajectories of decreased appetite were identified and named"decreased appetite aggravation group","mild decreased appetite maintenance group"and"decreased appetite exacerbation-relief group".Three trajectories of pain were identified,named"mild pain relief group","mild pain maintenance group"and"mild to moderate pain aggravation group".Logistic regression analysis showed that the age(OR=1.076,P=0.015)and targeted therapy(OR=10.743,P=0.009)were influential factors for fatigue.Duration of disease(OR=0.112,P=0.015),pemetrexed(OR=3.210,P=0.027)and targeted therapy(OR=7.077,P=0.032)were influential factors for pain.No influencing factors for decreased appetite have been identified.Conclusion:There is variability in the trajectory of symptom change in the fatigue-related symptom cluster in patients receiving immunotherapy for lung cancer.A small number of patients showed a trend of persistent worsening of appetite loss and pain.Future studies may continue to analyze intervention nodes based on symptom profile categories and help healthcare professionals identify key populations through influencing factors to provide personalized and holistic symptom management for patients with lung cancer receiving immunotherapy.
